Abstract
The last decade has brought a number of new data on the pathogenesis of rheumatoid arthritis (RA). A number of key molecules have been identified so far that participate in the pathogenesis of RA the targeted modification of which has become the basis for development of biological therapy.
Tofacitinib is a selective Janus kinases inhibitor that was included in a number of clinical follow-ups as part of the ORAL programme that focuses on patients with RA who underwent varying degrees of previous treatment with both conventional and biological drugs. Tofacitinib has demonstrated good efficacy and relatively good safety both in monotherapy and as part of combined therapy with methotrexate (MTX).
Data drawn from clinical studies resulted in the approval of tofacitinib dosed 5 mg twice daily orally for the therapy of moderately to highly active RA, in spite of administration of MTX. From June of 2018 is tofacitinib approved also for the treatment of psoriatic arthritis.
This review deals with tofacitinib as indicated for RA.
